Progressive efficacy improvements with quarterly intravenous ibandronate injections: The DIVA study long term extension

被引：0
|
作者：
Czerwinski, E.
Langdahl, B.
Stepan, J.
Grant, R.
Neate, C.
Bianchi, G.
机构：
[1] Krakow Med Ctr, Dept Med, Krakow, Poland
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Charles Univ Prague, Dept Internal Med, Prague, Czech Republic
[4] Hoffmann La Roche Inc, Nutley, NJ USA
[5] Roche Prod Ltd, Pharma Dev Med Biostat, Welwyn Garden City AL7 3AY, Herts, England
[6] Osped Coletta, Div Rheumatol, Genovese, Italy
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [41] 5-YEAR EFFICACY AND SAFETY OF ORAL MONTHLY IBANDRONATE: RESULTS OF THE MOBILE LONG-TERM EXTENSION STUDY
    Miller, Paul D.
    Recker, Robert R.
    Felsenberg, Dieter
    Reginster, Jean-Yves
    Riis, Bente Juel
    Czerwinski, Edward
    Lorenc, Roman
    Stakkestad, Jakob A.
    Dasic, Gorana
    Barr, Charles E.
    Lakatos, Peter
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S199 - S199
  • [42] Incidence of influenza-like symptoms with intermittent intravenous ibandronate injections:: 1-year results from DIVA
    Reid, DM
    Tankó, LB
    Felsenberg, D
    Adami, S
    Leigh, C
    Ward, P
    Masanauskaite, D
    Delmas, PD
    BONE, 2005, 36 : S425 - S425
  • [43] Pronounced increases in bone mineral density with intermittent intravenous ibandronate injections: 2-year results from DIVA
    Delmas, P. D.
    Eisman, J. A.
    Stepan, J.
    Hughes, C.
    Mairon, N.
    Masanauskaite, D.
    Felsenberg, D.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S12 - S12
  • [44] Favorable renal safety profile of intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from DIVA
    Delmas, P
    Reid, D
    Felsenberg, D
    Leigh, C
    Ward, P
    Sedarati, F
    Christiansen, C
    BONE, 2005, 36 : S419 - S420
  • [45] Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis
    Recker, R
    Stakkestad, JA
    Chesnut, CH
    Christiansen, C
    Skag, A
    Hoiseth, A
    Ettinger, M
    Mahoney, P
    Schimmer, RC
    Delmas, DP
    BONE, 2004, 34 (05) : 890 - 899
  • [46] Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results front DIVA.
    Recker, RR
    Reid, DM
    Sambrook, P
    Hughes, C
    Ward, P
    Bonvoisin, B
    Adami, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4095 - 4096
  • [47] Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
    Ringe, JD
    Dorst, A
    Faber, H
    Ibach, K
    Sorenson, F
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 (10) : 801 - 807
  • [48] Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
    J. D. Ringe
    A. Dorst
    H. Faber
    K. Ibach
    F. Sorenson
    Osteoporosis International, 2003, 14 : 801 - 807
  • [49] Favourable renal safety and tolerability profile of intravenous ibandronate injections in women with postmenopausal osteoporosis: 1-year results from diva
    Reid, DM
    Felsenberg, D
    Christiansen, C
    Leigh, C
    Ward, P
    Sedarati, F
    Delmas, PD
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 365 - 365
  • [50] Efficacy and adverse event profile of once-monthly oral ibandronate: Year 1 of the mobile long-term extension study
    Emkey, Ronald D.
    Miller, Paul D.
    Sedarati, Farhad
    Silverman, Stuart L.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S220 - S220
12345